登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002162 证券简称：悦心健康 公告编号：2025-033 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、误导性陈述或者重 大遗漏。 重要内容提示： 1、上海悦心健康集团股份有限公司（以下简称"公司"）拟使用自有资金或自筹资金以集中竞价交易的 方式回购公司部分已发行的人民币普通股（A股）股票（以下简称"本次回购股份"），回购股份将全部 用于注销并减少公司注册资本。本次回购总金额不低于人民币600万元（含）且不超过人民币1,000万元 （含），回购价格为不超过人民币5元/股（含），按回购价格上限5元/股测算，预计回购股份的数量区 间约为120万股至200万股，占公司目前总股本的比例区间约为0.13%至0.22%，回购股份的期限自股东 大会审议通过回购股份方案之日起不超过12个月，具体回购数量以回购期限届满时实际回购的股份数量 为准。 2、公司分别于2025年2月26日、2025年3月25日召开了第八届董事会第十三次会议、2024年度股东大 会，审议通过了《关于公司回购股份方案的议案》。 3、公司已在中国证券登记结算有限责任 ...

Core Viewpoint - Shanghai Yueshen Health Group Co., Ltd. has announced a share repurchase plan, aiming to buy back a portion of its issued A-shares to reduce registered capital, with a total repurchase amount between RMB 6 million and RMB 10 million [2]. Group 1 - The company held board meetings on February 26, 2025, and March 25, 2025, where the share repurchase plan was approved [2]. - The repurchase price will not exceed RMB 5 per share, with an estimated repurchase quantity ranging from 1.2 million to 2 million shares, accounting for approximately 0.13% to 0.22% of the total share capital [2]. - The repurchase period will last up to 12 months from the date of the shareholders' meeting approval [2]. Group 2 - As of March 31, 2025, the company has not yet implemented the share repurchase [3]. - The company will continue to execute the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by relevant laws and regulations [3].